BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36420560)

  • 1. Diffuse large B-cell lymphoma and red cell autoimmunity: clinical role and pathogenesis.
    Coombes C; Horikawa K; Jain S; Jiang S; Lim JH; Saxena K; Shadbolt B; Smyth L; Tobin J; Talaulikar D
    Pathology; 2023 Feb; 55(1):104-112. PubMed ID: 36420560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
    Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
    J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
    Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
    Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth.
    Hashwah H; Schmid CA; Kasser S; Bertram K; Stelling A; Manz MG; Müller A
    Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9701-9706. PubMed ID: 28831000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype.
    Sebastián E; Alcoceba M; Balanzategui A; Marín L; Montes-Moreno S; Flores T; González D; Sarasquete ME; Chillón MC; Puig N; Corral R; Pardal E; Martín A; González-Barca E; Caballero MD; San Miguel JF; García-Sanz R; González M
    Am J Pathol; 2012 Nov; 181(5):1879-88. PubMed ID: 22982190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
    Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
    EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.
    Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S
    Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL).
    Isshiki Y; Melnick A
    Curr Cancer Drug Targets; 2021; 21(4):274-282. PubMed ID: 33413063
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    García-Ramírez I; Tadros S; González-Herrero I; Martín-Lorenzo A; Rodríguez-Hernández G; Moore D; Ruiz-Roca L; Blanco O; Alonso-López D; Rivas JL; Hartert K; Duval R; Klinkebiel D; Bast M; Vose J; Lunning M; Fu K; Greiner T; Rodrigues-Lima F; Jiménez R; Criado FJG; Cenador MBG; Brindle P; Vicente-Dueñas C; Alizadeh A; Sánchez-García I; Green MR
    Blood; 2017 May; 129(19):2645-2656. PubMed ID: 28288979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS.
    Wang SS; Vajdic CM; Linet MS; Slager SL; Voutsinas J; Nieters A; Casabonne D; Cerhan JR; Cozen W; Alarcón G; Martínez-Maza O; Brown EE; Bracci PM; Turner J; Hjalgrim H; Bhatti P; Zhang Y; Birmann BM; Flowers CR; Paltiel O; Holly EA; Kane E; Weisenburger DD; Maynadié M; Cocco P; Foretova L; Breen EC; Lan Q; Brooks-Wilson A; De Roos AJ; Smith MT; Roman E; Boffetta P; Kricker A; Zheng T; Skibola CF; Clavel J; Monnereau A; Chanock SJ; Rothman N; Benavente Y; Hartge P; Smedby KE
    Cancer Epidemiol Biomarkers Prev; 2022 May; 31(5):1103-1110. PubMed ID: 35244686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.
    Huang YH; Cai K; Xu PP; Wang L; Huang CX; Fang Y; Cheng S; Sun XJ; Liu F; Huang JY; Ji MM; Zhao WL
    Signal Transduct Target Ther; 2021 Jan; 6(1):10. PubMed ID: 33431788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma.
    Zhang J; Vlasevska S; Wells VA; Nataraj S; Holmes AB; Duval R; Meyer SN; Mo T; Basso K; Brindle PK; Hussein S; Dalla-Favera R; Pasqualucci L
    Cancer Discov; 2017 Mar; 7(3):322-337. PubMed ID: 28069569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KMT2D acetylation by CREBBP reveals a cooperative functional interaction at enhancers in normal and malignant germinal center B cells.
    Vlasevska S; Garcia-Ibanez L; Duval R; Holmes AB; Jahan R; Cai B; Kim A; Mo T; Basso K; Soni RK; Bhagat G; Dalla-Favera R; Pasqualucci L
    Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2218330120. PubMed ID: 36893259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas.
    Lossos IS; Okada CY; Tibshirani R; Warnke R; Vose JM; Greiner TC; Levy R
    Blood; 2000 Mar; 95(5):1797-803. PubMed ID: 10688840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin's lymphoma (NHL).
    Aya-Bonilla C; Camilleri E; Haupt LM; Lea R; Gandhi MK; Griffiths LR
    BMC Genomics; 2014 May; 15(1):390. PubMed ID: 24885312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular osteopontin protects from autoimmunity-driven lymphoma development inhibiting TLR9-MYD88-STAT3 signaling.
    Rizzello C; Cancila V; Sangaletti S; Botti L; Ratti C; Milani M; Dugo M; Bertoni F; Tripodo C; Chiodoni C; Colombo MP
    Mol Cancer; 2022 Dec; 21(1):215. PubMed ID: 36503430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinicopathological and genetic features of ovarian diffuse large B-cell lymphoma.
    Xu H; Duan N; Wang Y; Sun N; Ge S; Li H; Jing X; Liang K; Zhang X; Liu L; Xue C; Zhang C
    Pathology; 2020 Feb; 52(2):206-212. PubMed ID: 31883669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
    Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
    Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma.
    Meyer SN; Scuoppo C; Vlasevska S; Bal E; Holmes AB; Holloman M; Garcia-Ibanez L; Nataraj S; Duval R; Vantrimpont T; Basso K; Brooks N; Dalla-Favera R; Pasqualucci L
    Immunity; 2019 Sep; 51(3):535-547.e9. PubMed ID: 31519498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups.
    Guo B; Huang Y; Duan Y; Liao C; Cen H
    Cancer Med; 2022 Mar; 11(5):1281-1291. PubMed ID: 35106936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.